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SUCCESSFUL islet transplantation (TR) has been 
shown to restore normoglycemia and prevent the 
development of chronic complications in diabetic ani-
mals. 1•2 Immune rejection is currently the major hindrance 
in the application of allo- and xeno-TR of pancreatic islets 
for the treatment of diabetes. We have shown earlier that 
FK 506 is an effective antirejection agent for fresh islet 
allografts across major histocompatibility barrier.3 The 
efficacy of FK 506 in the prolongation of islet allograft 
survival has been found to be influenced by the dosage of 
the FK 506 and the site of the islet graft. 3.4 In anticipation 
of the use of FK 506 as an immunosuppressive agent in 
human islet TR. its efficacy in various conditions similar to 
clinical TR needs to be examined. The present study was 
undertaken to determine whether FK 506 is effective in the 
prolongation of fresh islet allograft in recipients of islet 
grafts from one or two donor strains in two commonly 
used TR sites and also in previously sensitized diabetic 
recipient rats. 
MATERIALS AND METHODS 
Animals 
Male rats of outbred Wistar (Wi) and inbred Lewis (Le) strains 
Eoq-l~I with body weights of 350 to 500 g were used as donors of 
pancreatic tissue. and rats of inbred ACI (RT-la) strain were used 
as streptozotocin (STZ)-induced (55 mg/kg IV) diabetic recipients 
(Harlan Sprague Dawley, Indianapolis. Ind.). An animal is defined 
as diabetic only when serum glucose is greater than 400 mg/dL 
over 10 days. 
Islet Isolation and Transplantation 
Pancreatic tissue was digested with collagenase, and the islets 
were hand-picked under a dissection microscope. Contaminating 
acinar tissues and blood vessels were removed from the islets by 
the single-layer Hypaque-FicoU (H-F) separation technique.' For 
kidney subcapsular (KC) TR. approximately 2000 freshly isolated 
islets. suspended in a total volume of70 JLL Hanks' balanced salt 
solution (HBSS), were injected. For intraportal (lPo) TR. the 
islets were suspended in 200 JLL HBSS in a Monoject U-lOO 
insulin syringe and injected over a I-minute period into diabetic 
recipients. The syringe was flushed twice with the recipients' 
blood. 
FK 506 Treatment Protocol 
An injectable form of FK 506 (Lot 116393) was provided by 
Fujisawa Pharmaceutical Co (Osaka. Japan). The required 
amount of the compound was weighed out daily and prepared in 
saline within 10 minutes ofIM injection. The administration ofFK 
506 was initiated on the day ofTR. Protocol I consisted of FK 506 
at I mg/kg per day 1M for 2 weeks.PrptocollI consisted of FK 506 
1M administration at I mg/kg per day for 2 weeks followed by I 
mg/kg per week. 
Assessment of Graft Function 
Daily serum glucose and body weight of recipient rats were 
determined for 2 weeks after TR. and then twice weekly thereaf-
ter. Rejection was considered to have occurred when the serum 
glucose level exceeded 200 mg/dL for 3 successive days. Survival 
time for each recipient group is reported as mean :!: SEM. 
Statistical evaluation was performed using the Mann-Whitney U 
test. P < .05 was considered statistically significant. 
Assessment of the Efficacy of FK 506 in 
Sensitized Recipients 
After the rejection of the first islet allograft in a diabetic rat. a 
second islet graft from the same donor strain was performed in the 
contralateral kidney of the recipient. The second TR was per-
formed either a short or a long period after the first TR. The 
animals were treated with FK 506 protocol II. and their serum 
glucose monitored. 
RESULTS 
Table 1 shows the functional period of Wi and admixed Wi 
and Le islet allograft survival in two TR sites in diabetic 
ACI rats treated with two different FK 506 protocols. FK 
506 treatment at I mg/kg per day for 2 weeks significantly 
prolonged the survival of islet allograft transplanted both 
under KC and IPo. The survival was significantly longer in 
the IPo site than the KC site. (group 6 vs 4: 9 of 9 vs 3 of 
\0 functioned for over 4 months). In the KC site, the islet 
survival in recipients treated with FK 506 for 2 weeks was 
>71.8 ± 11.3 days (group 4), and this increased signifi-
cantly to> 171.4 ± 12.9 days (group 5) when an additional 
1M weekly injection of FK 506 was given. In the groups 
transplanted with a mixture of Wi and Le islets, FK 506 
treatment significantly improved the islet allograft func-
tional period over the untreated recipients (group 7 vs 3). 
Also. the group transplanted with the mixed islet allograft 
IPo had a longer functional period than the group trans-
planted under KC (group 8 vs 7). The efficacy of FK 506 
was less for mixed islet allograft than islets from a single 
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Table 1. Functional Period of WI and Admixture of WI and La Islet Allografts In Diabetic ACI Rats Immunosuppressed with FK 506 
Group Donor Site FK Rx' n Days Mean ~ SEM PValue 
Wi KC No 5 7, 7, 7, 8, 8 7.4 :!: 0.25 
2 Wi IPo No 6 5, 6, 6, 7, 8, 8 6.7 ± 0.50 
3 Wi + La KC No 5 4, 5, 5, 5, 7 5.2 ± O.SO 
4 Wi KC I 10 41,45,46,47,48.52,73. >120*, >122t, >124t 
>71.8± 11P~ 
.003 
5 Wi KC II 8 >112t , >114t , >182, >185, >191, >192, >195, >200 >171.4:!: 12.9 
.002 
6 Wi IPO 9 4x>122. >167, >190. >191, >193, >290 >168.6 ± 18.6 
7 Wi + La KC II 7 67,85, 90t , >98, 103, >115, 132 >98.6 ± 8.0 R~ 
.055 
8 Wi + La IPo II 7 98*,102,110,120, >172, >182, >183 >138.2:!: 14.7 
'Protocoll: FK 1 mgikg per day lor 2 weeks 1M: protocol II: FK 1 mglkg per day lor 2 weeks + weekly 1M. 
tNepinclomy. 
*Died 01 anesthesia. 
donor strain when TR was under KC but not IPo (group 7 
vs 5; 8 vs 6). Nephrectomy of the graft-containing kidney 
resulted in the return to hyperglycemia in 5 of 5 cases in 
ACI rats with long-term Wi (n = 4) or Wi + Le (n = I) islet 
allograft. 
Table 2 shows the efficacy of 1M FK 506 at 1 mg/kg per 
day for 2 weeks plus weekly treatment on islet allograft 
survival in diabetic ACI recipients which had previously 
rejected a Wi islet graft in the first TR performed 50 to 177 
days previously. The immunosuppression was effective in 
achieving long-term survival in 7 of7 recipients with 3 of7 
recipients achieving indefinite graft survival. This was not 
significantly different from that achieved in nonsensitized 
animals (Table 2 group 3 vs Table I group 5, P = .10). In 
contrast, when the interval between the first and second 
TR was of shorter duration. ie. 2 weeks. FK 506 immuno-
suppression was found to be ineffective. Nevertheless 
hyperacute rejection was not observed. 
DISCUSSION 
The present results show that FK 506 is an effective 
immunosuppressant in prolonging fresh islet allograft sur-
vival in rats across the MHC barrier. Significant prolonga-
tion of allograft survival was observed both under KC and 
IPo with 14 injections of I mg/kg FK 506. The efficacy of 
FK 506 treatment was improved by additional weekly 
injection in the group with islets transplanted under KC. 
This intermittent treatment regimen was effective in pro-
longing islet allograft survival composed of tissues from 
two donor strains. The observation is important. since islet 
tissue from more than one donor is needed to reverse the 
diabetic state of the recipients in clinical TR. 6 .7 Though 
FK 506 prolonged islet allograft from a single and two 
donor strains transplanted under KC. the result achieved 
in the former group was significantly better. One possible 
explanation is the higher immunogenicity of the mixed-
islet preparation from two donor strains. 
Earlier. Yasunami et al4 failed to achieve prolonged islet 
allograft under KC. The discrepancy could be due to the 
high dosage of FK 506 for a longer duration used by us. 
The route of TR seems to be important as we observed the 
superiority of the IPo over the KC site in the islet TR 
model. This finding confirms previous observations.4 The 
suggestion that FK 506 is metabolized extensively in the 
liver before excretion may contribute to the superiority of 
the IPo site.8 
Despite voluminous literature on the effect of various 
immunosuppressive agents and islet pretreatment on the 
successful outcome of islet allo-TR in nonsensitized ro-
dents, relatively little information is available for sensi-
tized animals. The present data demonstrated that FK 506 
was very effective in prolonging the second islet allograft 
survival in sensitized rats provided the interval between 
Table 2. Effect of FK 506 Treatment on Functional Islet Allograft Survival Under Kidney Capsule In Presensltlzed ACI Rats· 
Days 1st 10 
Group Donor 2ndTA FK Axt n Days Mean:!: SEM 
Wi No No 4 5.6,7,7 6.25:!: 0.48 
2 Wi 104.0 :!: 3.2 No 4 7, 7, 7, 8 7.25:!: 0.25 
3 Wi 115.6 ± 21.6 II 7 59,78,99,113, >141, >198, >128.3:!: 21.9 
>210 
4 Wi 14.2 :!: 0.2 II 5 5,5.10,11,34 13.0:!: 5.4 
'Sensitization was achieved by fresh Wi islet allograft under kidney capsule. 
tprotocoill: FK 1 mglkg per day lor 2 week!eD~eekly 1M. 
3210 
the initial and second islet transplants was sufficient for the 
antidonor immune activities to subside. Though FK 506 
treatment failed to prolong the rat islet allograft in recently 
sensitized recipients. in no instance was hyperacute rejec-
tion observed in the animals. with or without FK 506 
immunosuppression. 
In conclusion. FK 506 treatment is effective in prolong-
ing islet allograft survival in recipients of islets from a 
single- or dual-donor strain. In sensitized recipients. the 
long interval between the initial and second transplant is 
crucial to the survival of the second transplant using FK 
506 as immunosuppressive agent. Further modifications of 
the treatment protocol are needed to improve the efficacy 
of the drug in highly sensitized recipients. 
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